Physician profile
John E Reesor
NPI 1447255922
$3,214.69
in general payments reported to CMS, 2019-2025
37 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $123 · 2021: $369 · 2022: $581 · 2023: $550 · 2024: $648 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,697 · Education: $12.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,697.33 |
| Education | $12.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $552.68 | 2019-2025 | |
| Lilly USA, LLC | $421.64 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $225.75 | 2019-2022 | |
| Glaxosmithkline, LLC. | $178.04 | 2020-2025 | Trelegy Ellipta, Pediarix, Bexsero |
| Otsuka America Pharmaceutical, INC. | $158.07 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Antares Pharma, INC. | $145.70 | 2021-2024 | Xyosted |
| Pfizer INC. | $117.92 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $114.37 | 2024-2025 | Fanapt |
| Novo Nordisk INC | $105.63 | 2021-2024 | Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $87.88 | 2024 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.39 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.37 | 2020-2023 | Trintellix |
| Amgen INC. | $75.69 | 2019-2022 | |
| Astellas Pharma US INC | $72.23 | 2019-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company Ltd. | $67.89 | 2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Reesor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.